{
    "clinical_study": {
        "@rank": "72303", 
        "arm_group": [
            {
                "arm_group_label": "Metadoxine", 
                "arm_group_type": "Experimental", 
                "description": "Metadoxine 500 mg tablets by mouth every 12 hours for 6 months and metformin 500 mg tablets  by mouth every 8 hours for 6 months"
            }, 
            {
                "arm_group_label": "Placebo tablet", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo  tablet (for Metadoxine) by mouth every 12 hours for 6 months and metformin 500 mg tablets by mouth every 8 hours for 6 months"
            }
        ], 
        "brief_summary": {
            "textblock": "Oxidative stress is produced by imbalance between reactive oxygen species and antioxidant\n      systems. This state is frequently associated with chronic diseases like obesity, insulin\n      resistance, metabolic syndrome and hepatic steatosis. In the liver, the oxidative stress may\n      trigger the progression of fatty liver disease, from triglyceride accumulation to\n      inflammation, cirrhosis and hepatocellular carcinoma. Thus, the attenuation of oxidative\n      stress, could be an important therapeutic target to lessen the severity of the disease.\n      Until now,  there is not a medical treatment to cure non-alcoholic fatty liver disease, but\n      therapies aimed at reducing oxidative stress  have been proposed. Metadoxine, an ionic\n      complex of pyridoxine-pyrrolidone molecule, acts as a synthetic antioxidant, forming traps\n      that can reduce free radicals; likewise, metadoxine has a proven capacity to reduce fat\n      liver in alcoholic hepatitis. Finally, in fact that  alcoholic and non-alcoholic liver\n      diseases share molecular mechanisms in the generation of oxidative stress, the investigators\n      propose metadoxine as a posssible modifier of the oxidative stress in non-alcoholic liver\n      disease, prediabetic patients."
        }, 
        "brief_title": "Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "NAFLD", 
            "Pre-diabetes"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glucose Intolerance", 
                "Prediabetic State"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female\n\n          -  18 to 65 years old\n\n          -  Ultrasonographic diagnosis of NAFLD\n\n          -  Prediabetes diagnosis\n\n        Exclusion Criteria:\n\n          -  Alcoholism\n\n          -  Hepatitis C or B Virus Infection\n\n          -  Pregnancy\n\n          -  Autoimmune hepatitis\n\n          -  Metformin or metadoxine allergy\n\n          -  Parenteral nutrition in the last month\n\n          -  Weigh loss greater than 10% in the last month\n\n          -  Taking vitamin supplements in the last month"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02051842", 
            "org_study_id": "GAS-1081-13/14-1"
        }, 
        "intervention": {
            "arm_group_label": "Metadoxine", 
            "intervention_name": "Metadoxine", 
            "intervention_type": "Drug", 
            "other_name": [
                "Metadoxil", 
                "Abrixone"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Metadoxine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "NAFLD", 
            "oxidative stress", 
            "malondialdehyde"
        ], 
        "lastchanged_date": "March 12, 2014", 
        "location": {
            "contact": {
                "email": "detoal@yahoo.com", 
                "last_name": "Aldo Torre, M.D, M.Sc.", 
                "phone": "54870900", 
                "phone_ext": "2711"
            }, 
            "facility": {
                "address": {
                    "city": "Mexico City", 
                    "country": "Mexico", 
                    "zip": "14000"
                }, 
                "name": "Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n \"Salvador Zubir\u00e1n\""
            }, 
            "investigator": [
                {
                    "last_name": "Aldo Torre, MD MSci", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Leonardo Martinez, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients", 
        "other_outcome": [
            {
                "description": "Malondialdehyde levels", 
                "measure": "Oxidative stress", 
                "safety_issue": "No", 
                "time_frame": "3 month follow-up"
            }, 
            {
                "description": "Malondialdehyde levels", 
                "measure": "Oxidative stress", 
                "safety_issue": "No", 
                "time_frame": "6 months follow-up"
            }
        ], 
        "overall_contact": {
            "email": "detoal@yahoo.com", 
            "last_name": "Aldo Torre, M.D., M.Sc.", 
            "phone": "54870900", 
            "phone_ext": "2711"
        }, 
        "overall_official": {
            "affiliation": "Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran", 
            "last_name": "Aldo Torre, MD MSci", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Mexico: Secretaria de Salud", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Malondialdehyde levels", 
            "measure": "Oxidative stress", 
            "safety_issue": "No", 
            "time_frame": "Baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02051842"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran", 
            "investigator_full_name": "ALDO TORRE DELGADILLO", 
            "investigator_title": "Principal investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}